<DOC>
	<DOCNO>NCT02347774</DOCNO>
	<brief_summary>This trial 12 week treatment nebulized SUN-101 use Investigational eFlow® Closed System ( CS ) nebulizer subject chronic obstructive pulmonary disease ( COPD ) accord Global Initiative Chronic Obstructive Lung Disease ( GOLD 2014 ) guideline .</brief_summary>
	<brief_title>Efficacy Safety Trial 12 Weeks Treatment With Nebulized SUN-101 Patients With COPD ( GOLDEN-4 )</brief_title>
	<detailed_description>This Phase 3 , randomize , double-blind , placebo-controlled , parallel-group , multicenter , efficacy safety trial 12 week treatment nebulized SUN-101 use Investigational eFlow® Closed System ( CS ) nebulizer approximately 645 subject chronic obstructive pulmonary disease ( COPD ) accord Global Initiative Chronic Obstructive Lung Disease ( GOLD 2014 ) guideline . SUN-101 placebo administer twice daily oral inhalation use investigational eFlow CS nebulizer .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>1 . Male female patient age ≥ 40 year , inclusive 2 . A clinical diagnosis COPD accord GOLD 2014 guideline 3 . Current smoker exsmokers least 10 packyear smoke history ( eg , least 1 pack/day 10 year , equivalent ) 4 . Postbronchodilator ( follow inhalation ipratropium bromide ) FEV1 &lt; 80 % predict normal &gt; 0.7 L Screening ( Visit 1 ) 5 . Postbronchodilator ( follow inhalation ipratropium bromide ) FEV1/FVC ratio &lt; 0.70 Screening ( Visit 1 ) 6 . Ability perform reproducible spirometry accord American Thoracic Society ( ATS ) European Respiratory Society ( ERS ) guideline ( 2005 ) 7 . Subject , female ≤ 65 year age child bear potential , must negative serum pregnancy test Visit 1 . Females childbearing potential must instruct agree avoid pregnancy study must use acceptable method birth control : ) oral contraceptive , intrauterine device ( IUD ) , implantable contraceptive , transdermal injectable contraceptive least 1 month prior enter study continue use throughout study thirty day follow participation ; b ) barrier method contraception , eg , condom /or diaphragm spermicide participate study ; and/or c ) abstinence 8 . Willing able provide write informed consent 9 . Willing able attend study visit adhere study assessment procedure 1 . Severe comorbidities include unstable cardiac pulmonary disease medical condition would , opinion Investigator , preclude subject safely complete require test study , likely result disease progression would require withdrawal subject 2 . Concomitant clinically significant respiratory disease COPD ( eg , asthma , tuberculosis , bronchiectasis nonspecific pulmonary disease ) . 3 . Recent history COPD exacerbation require hospitalization need increase treatment COPD within 6 week prior Screening ( Visit 1 ) . 4 . Use daily oxygen therapy &gt; 12 hour per day 5 . Respiratory tract infection within 6 week prior Screening ( Visit 1 ) 6 . Use oral , intravenous , intramuscular steroid within 3 month prior Screening ( Visit 1 ) 7 . History malignancy organ system , treat untreated within past 5 year , exception localize basal cell carcinoma skin 8 . Prolonged QTcF ( &gt; 450 msec male &gt; 470 msec female ) Screening ( Visit 1 ) determine report provide central laboratory , history long QT syndrome 9 . History clinically significant ongoing bladder outflow obstruction history catheterization relief bladder outflow obstruction within previous 6 month 10 . History narrow angle glaucoma 11 . History hypersensitivity intolerance aerosol medication 12 . Recent documented history ( within previous 3 month ) substance abuse 13 . Significant psychiatric disease would likely result subject able complete study , opinion Investigator 14 . Participation another investigational drug study drug receive within 30 day prior Screening ( Visit 1 ) current participation another investigational drug trial , include SUN101 study 15 . Previously receive SUN101 ( active treatment ; formerly know EP101 ) 16 . Contraindicated treatment , history reactions/hypersensitivity anticholinergic agent , beta2 agonist , sympathomimetic amine</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>COPD</keyword>
</DOC>